CBA Florida Inc. (fka CBAI)

[MrLong]

Forgot to mention in September 2010 all insurance companies pay for storage to treat under a growing list of proven FDA UCB therapies. To force insurance companies to comply what does the new healthcare law require insurance groups to do? Pay for all genetic testing of pregant moms and newborns. If a problem is detected in the blood they must pay to cryostore it. What does that do for demand for U.S. storage?

There are 4.2 million births annually in the U.S. On average 150 birth defects alone each yr. Last year new U.S. Leukemia cases amounted to 1.5 million; all given the big green light to treat with UCBs as "routine care" and no longer "investigational" or "experimental". The same for sickle cell, thalassemia etc. That was the loophole insurance groups used to deny. If "experimental" or "investigational" it was a challenge to get them to pay.

The gov't has also commissioned a panel to look at Orphan drugs that can be spead up through the process to get regulatory approval. These were held up by the FDA. We are inches from the finishline of a marathon race.

So add in diabetes, parkinson's, cerebral palsy, and many other stem cell treatable diseases and disorders to the tune of millions in need of a treatment and I see major demand for storage and our capacity is +250 million.

"It's money time!"